Authorized Generic or ANDA Generic: How to Verify the NDA Relationship

What the Documents Mean by Authorized Generic

When market access directors, hospital formulary managers, and claims adjudicators encounter an unbranded drug package on a wholesaler ledger, they face a high-consequence classification question: is this National Drug Code (NDC) an independent generic approved through an Abbreviated New Drug Application (ANDA), or is it the brand manufacturer's authorized generic marketed under the original New Drug Application (NDA)?

The operational answer cannot be resolved by looking at the physical carton, reading the packager trade name, or checking consumer pricing tools. FDA's authorized-generics explainer states the point directly: an authorized generic is an approved brand-name drug marketed without the brand name on its label. Other than that labeling difference, it is the exact same drug product as the branded product. An authorized generic is not a separate generic approval. Legally, it is the brand company's 505(c) listed drug—approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act)—marketed under that same New Drug Application, not a separate Abbreviated New Drug Application (ANDA). FDA may allow a different color or marking on an authorized generic tablet or capsule; inhaler trade dress can differ while the product remains on the original NDA.

The formal statutory baseline is codified at 21 U.S.C. § 355(t)(3) (added by Section 920 of the Food and Drug Administration Amendments Act of 2007, FDAAA) and mirrored verbatim in FDA's core procedural regulations at 21 CFR 314.3. Under these provisions, an authorized generic drug is defined as a listed drug that has been approved under section 505(c) of the FD&C Act and is marketed, sold, or distributed directly or indirectly to the retail class of trade under a different labeling, packaging (other than repackaging for institutional use), product code, labeler code, trade name, or trademark than the listed drug.

By sharp contrast, a commonly understood generic drug is developed and manufactured by an independent pharmaceutical sponsor under section 505(j) through an ANDA. The ANDA applicant must prove pharmaceutical sameness to the reference listed drug—demonstrating identical active pharmaceutical ingredient (API), route of administration, dosage form, strength, conditions of use, and bioequivalence—while navigating patent certifications and permissible labeling carve-outs. An ANDA introduces an independent therapeutic copy; an authorized generic introduces no new drug dossier. See generic entry, ANDA, and 505(b)(2): the commercial difference.

The operational distinction between brand NDA, authorized generic, and independent ANDA generic ripples across every dimension of pharmaceutical supply, claims adjudication, and government pricing. Table 1 summarizes the defining regulatory parameters across all three presentations.

The Labeler and Marketing Relationship Verification Protocol

To determine whether an unfamiliar or generic-appearing NDC represents an authorized generic, reimbursement analysts, claims adjudicators, and market access teams must execute a disciplined source-document audit. Guesswork based on packaging or wholesaler descriptions creates identity errors that later programs cannot repair. Teams should trace the three identity checks, then the program rules, shown in Diagram 1.

flowchart TD
    A["Input unknown generic-looking NDC"] --> B["Step 1: DailyMed / FDA NDC Directory"]
    B --> C{"Marketing category"}
    C -->|"NDA authorized generic"| D["Read application number"]
    C -->|"ANDA"| E["Independent generic: 505(j) ANDA"]
    C -->|"Other / relabel / repack"| F["Not an authorized generic on this field"]
    D --> G{"Application number is the brand NDA?"}
    G -->|"Yes"| H["Treat as NDA authorized generic"]
    G -->|"No"| I["Discrepancy: re-read the SPL"]
    H --> J["Step 2: FDA quarterly AG list"]
    J --> K["Record trade name, NDA holder, reported entry period"]
    H --> L["Step 3: Orange Book / Drugs@FDA"]
    L --> M["Confirm active NDA row; no standalone AG row"]
    H --> N["Then apply the matching program rules"]
    N --> O["Medicaid: 42 CFR 447.502 / 447.506"]
    N --> P["180-day exclusivity: ANDA-to-ANDA only"]
    N --> Q["Plan MAC / DAW / formulary file in use"]

Step 1: Parsing NDC Segments and DailyMed SPL Listings

Under 21 CFR 207.33, the National Drug Code is a 10- or 11-digit numerical identifier structured into three distinct segments: the labeler code, the product code, and the package code. The labeler code is assigned directly by the FDA to any entity that manufactures, repacks, relabels, or distributes a finished drug. When evaluating an NDC, claims teams must never rely solely on the printed company name. A manufacturer string on a label can be identical across different legal entities while the underlying labeler code indicates separate distribution lines. See NDC lookup for claims teams: reading labeler, product, and package codes before you bill.

The definitive source-document check occurs in the DailyMed Structured Product Labeling (SPL) database maintained by the National Library of Medicine, alongside the FDA NDC Directory. Within the DailyMed XML/SPL header, operators must inspect two mandatory regulatory fields:

• Marketing Category: For an authorized generic, this field is explicitly coded as New Drug Application Authorized Generic (or NDA authorized generic). An independent generic is coded as Abbreviated New Drug Application (ANDA), while the innovator brand is coded as New Drug Application (NDA).

• Application Number: For an authorized generic, the application number references the innovator's original 505(c) dossier—formatted as NDA followed by six digits (e.g., NDA021929). If the package represents an independent generic, the field will reference an ANDA dossier (e.g., ANDA211699).

Step 2: Cross-Referencing FDA's Public Listing of Authorized Generics

Under Section 505(t) of the FD&C Act (21 U.S.C. § 355(t)), FDA must publish a list of authorized generic drugs reported in NDA annual reports after January 1, 1999—including trade name, brand company manufacturer, and the date the authorized generic entered the market—and update that list quarterly. Under postmarketing reporting rules codified at 21 CFR 314.81(b)(2)(ii)(b), NDA holders are legally obligated to report in their annual reports the date each authorized generic entered the market, the date each ceased being distributed, and the corresponding brand trade name, itemizing each dosage form and strength separately.

While the quarterly FDA Listing of Authorized Generics serves as a vital historical baseline, trade access teams must understand its technical design limits. As explicitly noted in FDA's July 2, 2026 listing release, the publication is compiled retrospectively from sponsor annual report filings. The recorded 'date entered market' frequently reflects the beginning of the annual reporting period rather than the exact calendar day of commercial release. Furthermore, subsequent marketing transfers and cessation dates are often unknown to the agency. Consequently, an entry on the FDA quarterly list confirms that an authorized generic relationship was established, but it does not certify that the product is actively flowing through commercial wholesale channels today.

Step 3: Orange Book and Drugs@FDA Confirmation

Once the DailyMed application number is established, analysts must query the Orange Book or Drugs@FDA database using the six-digit application number. This audit step confirms two facts: first, that the underlying brand NDA remains in the Active Section of the publication; and second, whether any independent 505(j) ANDAs have entered the multisource market. Table 2 lists the fields to inspect in each source system. Once independent ANDAs are approved with therapeutic equivalence ratings (such as AB), the brand NDA is no longer single-source. The authorized generic remains the same NDA-approved listed drug. See Orange Book therapeutic equivalence: 48K products, 55% single-source, AB dominates.

Public-Record Case Study: Budesonide/Formoterol (Symbicort)

To demonstrate how these primary source documents interact in practice, we examine the public regulatory records for budesonide and formoterol fumarate dihydrate inhalation aerosol (reference listed drug: Symbicort, NDA 021929). This case provides an ideal paradigm because the marketplace includes the original brand product, an authorized generic distributed under the brand NDA, and independent ANDA generics approved under section 505(j).

All data points in Table 3 reflect verified regulatory filings from the FDA Quarterly Authorized Generic List (as of July 2, 2026), Drugs@FDA, and DailyMed SPL records current as of September 21, 2026.

Dissecting the Public Record Findings

Evaluating the Symbicort public record yields three crucial insights that protect access teams from common operational errors:

1. The Packager Name Trap: AstraZeneca Pharmaceuticals LP is listed as the packager on both the brand-name Symbicort listing (setid fafa4cf1...) and the authorized generic listing (setid 1d266fe8...). An analyst relying on company name alone would observe no corporate distinction. However, the labeler code shifts from 0186 (AstraZeneca's primary brand labeler) to 0310 (an alternative AstraZeneca labeler code on the same packager string). The labeler code shift, coupled with the marketing category designation NDA authorized generic, defines the regulatory relationship under 21 CFR 314.3.

2. Exclusion from Standalone Orange Book Rows: Drugs@FDA lists NDA 021929 for AstraZeneca, ANDA 211699 for Mylan (Breyna), and ANDA 212212 for Teva Pharmaceuticals USA Inc. There is no separate entry for AstraZeneca's unbranded budesonide/formoterol. The authorized generic exists within NDA 021929: it is the same 505(c) listed drug as the brand presentation, not a separately approved ANDA copy.

3. Chronological Decoupling from ANDA Approvals: The FDA Authorized Generic list records AstraZeneca's reported market-entry period as January 2020. FDA approved Mylan's Breyna on March 15, 2022; DailyMed records a marketing start of July 31, 2023. The authorized generic was already on the annual-report list more than two years before that ANDA approval. That sequence shows an NDA-marketed authorized generic is not waiting on ANDA approval. It is not a 180-day exclusivity or forfeiture determination for Mylan or any first applicant.

What That Identity Changes, by Program

Fixing the regulatory identity of an NDC as an authorized generic rather than an independent ANDA generic is not an academic exercise. It fundamentally alters statutory rebate obligations under Medicaid, dictates the applicability of 180-day generic exclusivity under Hatch-Waxman, and governs pharmacy substitution mechanics under state law.

1. Medicaid Drug Rebate Program: Innovator vs. Noninnovator Classification

Under the Medicaid Drug Rebate Program (MDRP), drug classification dictates the statutory rebate formula applied to state utilization. Under 42 CFR 447.502, an authorized generic drug is defined as any drug sold, licensed, or marketed under an NDA approved under section 505(c) of the FD&C Act that is distributed under a different labeler code, product code, trade name, trademark, or packaging than the brand-name drug.

Crucially, 42 CFR 447.502 classifies an authorized generic marketed under an NDA as an innovator multiple source drug ('I'), explicitly including the original NDA holder within the statutory definition of manufacturer. In contrast, an independent generic approved under section 505(j) is classified as a noninnovator multiple source drug ('N').

This distinction changes which Medicaid rebate formula applies:

• Rebate Formula: Innovator multiple source drugs, including authorized generics marketed under an NDA, use the Medicaid innovator rebate formula: a basic rebate equal to the greater of a statutory percentage of Average Manufacturer Price (AMP) or the AMP-to-best-price difference, plus a CPI-U additional rebate when AMP outpaces inflation. The usual basic-rebate percentage is 23.1% of AMP (17.1% for clotting factor and drugs approved exclusively for pediatric indications). Noninnovator ANDA drugs use a 13% of AMP basic rebate, are not in the best-price computation, and can also owe a CPI-U additional rebate. Mapping an authorized generic onto the noninnovator class applies the wrong rebate formula.

• Primary vs. Secondary Manufacturer Allocation (42 CFR 447.506): Federal regulations draw a sharp dividing line based on corporate distribution structure. The primary manufacturer is the NDA holder. Under 42 CFR 447.506(b), when calculating the AMP of its brand-name product, the primary manufacturer must exclude any sales of authorized generic drugs to wholesalers for drugs distributed to retail community pharmacies. Under 42 CFR 447.506(c), the primary manufacturer includes the authorized generic's Best Price in the brand's Best Price calculation only when the authorized generic is being sold directly by the manufacturer holding the NDA. If the authorized generic is licensed to a separate secondary manufacturer, that secondary entity must maintain its own Medicaid rebate agreement, report its own AMP and Best Price under 42 CFR 447.504 and 447.505, and pay statutory rebates on its own sales.

Compliance teams managing Medicaid best-price risk in value-based drug contracts must verify whether their authorized generic is distributed internally or through an external partner before establishing gross-to-net accounting reserves.

2. Hatch-Waxman 180-Day Exclusivity: An ANDA-to-ANDA Clock

Under Section 505(j)(5)(B)(iv) of the FD&C Act (21 U.S.C. § 355(j)(5)(B)(iv)), the first applicant to submit a substantially complete paragraph IV ANDA is awarded 180 days of market exclusivity against subsequent ANDA filers. Commercial teams often wonder: does an authorized generic violate or forfeit the first generic applicant's 180-day exclusivity window?

The statutory answer is no: 180-day exclusivity does not approve or block the NDA holder's authorized generic. As defined in 21 U.S.C. § 355(j)(5)(B)(iv) and 21 CFR 314.3, the 180-day exclusivity period operates exclusively between ANDA applicants. It prevents the FDA from making subsequent paragraph IV ANDAs effective until 180 days after commercial marketing by a first applicant. Because an authorized generic is marketed under the pre-existing 505(c) NDA, it is not an ANDA and requires no secondary FDA approval. FDA's 180-day clock therefore does not bar the NDA presentation—before patent expiration, during the ANDA exclusivity window, or after generic entry. Private patent settlements can still restrict a particular launch; this article does not read those contracts. In our detailed Hatch-Waxman 180-day exclusivity forfeiture guide, we examine how first applicants navigate generic entry alongside authorized generic competition.

3. Pharmacy Substitution, MAC Lists, and Formularies

The intersection of authorized generics with commercial pharmacy benefit design presents frequent billing friction. FDA considers an authorized generic therapeutically equivalent to the brand because it is the same drug. The Orange Book Preface assigns substitution policy to the states, which generally encourage substitution through positive- or negative-formulary statutes. Because authorized generics are not separately itemized with an AB code, a pharmacy system that looks only for a standalone Orange Book TE row may require a manual override or a specific DAW (Dispense as Written) code. That is a state-law and plan-file question after identity is fixed, not an FDA coverage decision.

Furthermore, PBMs and health plans treat authorized generics inconsistently:

• Formulary Tiering: Some plans put an authorized generic on a generic copay tier; others treat it as brand or apply a distinct MAC or DAW rule. The FDA identity check does not pick the tier. Read the formulary or PDL file in use.

• Maximum Allowable Cost (MAC): PBMs may place an authorized generic on a MAC schedule alongside ANDA generics or maintain it under WAC-based reimbursement depending on network contracting terms.

• NADAC Acquisition Benchmarks: NADAC and wholesaler files may flag an authorized generic as 'generic' because the NDC is unbranded. That flag is not an ANDA determination. Use the current NADAC file as a pricing file, not as FDA identity. See CMS NADAC by the numbers.

Verification Limits, Annual-Report Lag, and Operational Warnings

While federal databases provide dated document trails, access and reimbursement leaders must recognize the lag built into annual-report extracts. Relying on those files without their operational limits misreads identity.

Three Critical Document Traps

1. The Annual-Report Latency Trap: The FDA Listing of Authorized Generics is updated quarterly, but its underlying data is derived entirely from NDA annual reports submitted under 21 CFR 314.81(b)(2). Because annual reports are due within 60 days of the NDA anniversary date, an authorized generic may not appear on the public list until after the next reporting cycle, which can lag many months. Cessation dates are often unknown. The absence of an NDC from the quarterly list does not prove it is not an authorized generic; DailyMed SPL category verification must remain the primary test.

2. The Wholesaler 'Generic' Flag Fallacy: Wholesaler ordering portals, pharmacy management software, and claims adjudicators frequently assign a binary 'Generic' flag to authorized generics simply because they carry an unbranded chemical name or lower list price. A commercial label in a wholesaler catalog is not a legal determination that the product was approved under section 505(j). Claims teams that map wholesaler generic flags into Medicaid rebate or pricing systems risk applying the wrong rebate class.

3. The Private-Label Distributor Confusion: When an innovator contracts with an external distributor or private-label packager, the resulting NDC carries the partner's labeler code. If analysts stop their audit at the labeler code, they may assume the drug is an independent generic or an unapproved entity. Inspecting the DailyMed XML header for the underlying NDA application number instantly resolves the relationship.

By anchoring every NDC classification in primary regulatory documents—DailyMed SPL metadata, 21 CFR 314.3 definitions, Orange Book active application records, and 42 CFR 447.506 Medicaid rebate rules—launch, access, and reimbursement teams can keep substitution, rebate, and exclusivity questions on the correct source document.

Sources and Reference Documents

This analysis is grounded entirely in public statutory provisions, federal regulations, official agency databases, and published manufacturer regulatory filings. Primary source documents include:

• U.S. Food and Drug Administration: FDA List of Authorized Generic Drugs — Overview of authorized generic concepts, statutory authorities under FDAAA, and links to public databases.

• U.S. Food and Drug Administration: FDA Listing of Authorized Generics (as of July 2, 2026) — Quarterly public extract of authorized generic drugs reported in NDA annual reports since January 1, 1999.

• 21 U.S.C. § 355 — New Drugs (including Section 505(c), 505(j), and 505(t)) — Federal Food, Drug, and Cosmetic Act statutory provisions establishing NDA, ANDA, and authorized generic frameworks.

• 21 CFR 314.3 — Definitions (Food and Drugs, FDA) — Regulatory definitions for authorized generic drug, listed drug, NDA, ANDA, first applicant, and therapeutic equivalents.

• 21 CFR 314.81 — Other Postmarketing Reports — Annual reporting obligations for NDA holders regarding authorized generic market entry, cessation, and product descriptions.

• U.S. Food and Drug Administration: Orange Book Preface — Policy on therapeutic equivalence, single-source products, and the non-listing of distributors and repackagers.

• U.S. Food and Drug Administration: Orange Book Questions and Answers Guidance for Industry — Formal guidance addressing why authorized generics are not separately listed in the Orange Book (Footnote 15).

• National Library of Medicine DailyMed: SYMBICORT Inhalation Aerosol — Structured Product Labeling for NDA 021929 under AstraZeneca primary labeler code 0186.

• National Library of Medicine DailyMed: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE Aerosol (NDA Authorized Generic) — Structured Product Labeling for NDA 021929 authorized generic under labeler code 0310.

• National Library of Medicine DailyMed: BREYNA Aerosol Metered — Structured Product Labeling for ANDA 211699 under Mylan Pharmaceuticals labeler code 0378.

• U.S. Food and Drug Administration Drugs@FDA: NDA 021929 SYMBICORT — Application approval history, active status, therapeutic equivalence ratings, and reference standard designations.

• U.S. Food and Drug Administration Office of Generic Drugs: ANDA 211699 Approval Letter (Breyna) — Approval letter granting therapeutic equivalence and addressing 180-day exclusivity under 505(j)(5)(B)(iv).

• 21 CFR 207.33 — What is the National Drug Code (NDC), How Is It Assigned, and What Are Its Requirements? — Regulatory requirements governing NDC configuration, labeler codes, product codes, and package types.

• U.S. Food and Drug Administration: National Drug Code Directory — Daily updated finished drug listing database submitted by registered pharmaceutical labelers.

• 42 CFR 447.502 — Definitions (Medicaid Drug Rebate Program) — Centers for Medicare & Medicaid Services definitions classifying authorized generics as innovator multiple source drugs.

• 42 CFR 447.506 — Authorized Generic Drugs (Medicaid Drug Rebate Program) — Statutory rules governing Average Manufacturer Price exclusion and Best Price inclusion for primary and secondary manufacturers.